Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MYO vs MBOT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MYO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–6 Matrix Metrics)
MYO Overall Winner
6-Pillar Tally: MYO 4 – 1 MBOT (1 Tie)
Matrix Metrics: MYO 4 – 6 MBOT
As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over Microbot Medical, Inc. (MBOT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas MBOT carries 54.9/100 (HOLD) at $0.68 (31.8x Forward P/E, -5057.2% operating margin).
- Composite vs. Pillar Nuance: While MBOT currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -5057.2% operating margin) and revenue trajectory (+22.2% vs. +0.0% YoY).
- Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile MBOT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MYO vs MBOT
MYO
Head-to-Head Winner
Myomo Inc.
$0.81
-3.45% 1D
Market Cap
$33.7M
TTM Revenue
$46M
Forward P/E
N/M
Beta / 30D Vol
2.22β · 107% Vol
Unified Composite Score
40.1
SELL
Tech 25.0
Fund 43.0
Flow 58.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
MBOT
Microbot Medical, Inc. Common Stock
$0.68
-8.52% 1D
Market Cap
$49.9M
TTM Revenue
$418,000
Forward P/E
31.8x
Beta / 30D Vol
1.68β · 145% Vol
Unified Composite Score
54.9
HOLD
Tech 48.0
Fund 55.0
Flow 68.0
Mom 49.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MYO 4 – 1 MBOT)
1. Valuation Multiples
MBOT
Forward P/E
N/M
31.8x
Trailing P/E
N/M
31.8x
PEG Ratio
N/M
0.70x
EV / Revenue
0.9x
115.9x
2. Growth & Scale
MYO
Revenue Growth (YoY)
+22.2%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$46M
$418,000
Market Cap
$33.7M
$49.9M
3. Profitability & Quality
MYO
Gross Margin
70.1%
N/A
Operating Margin
-21.8%
-5057.2%
Net Profit Margin
-33.1%
0.0%
Return on Equity (ROE)
-173.5%
-26.3%
4. Balance Sheet & Cash Flow
MYO
Cash Generation (TTM)
-$9.1M
-$20M
Cash Flow Margin
-20.0%
N/A
Net Cash / Leverage
$8.9M Net Debt (3.44x D/E)
$1.5M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MYO
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
266.0% (81st %ile)
112.5% (30th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MYO (4) vs MBOT (6)| Institutional Metric | MYO | MBOT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $33.7M | $49.9M | MBOT | |
| Trailing P/E Ratio | N/M | 31.8x | MBOT | |
| Forward P/E Ratio | N/M | 31.8x | MBOT | |
| Revenue Growth (YoY) | +22.2% | +0.0% | MYO | |
| Operating Margin (TTM) | -21.8% | -5057.2% | MYO | |
| Net Profit Margin | -33.1% | 0.0% | MBOT | |
| Return on Equity (ROE) | -173.5% | -26.3% | MBOT | |
| 52-Week Range Position | 16% ($1–$2) | 7% ($1–$3) | MYO | |
| Beta / 30D Volatility | 2.22β · 107% Vol | 1.68β · 145% Vol | MYO | |
| Unified Institutional Score | 40.1 / 100 (SELL) | 54.9 / 100 (HOLD) | MBOT | |
| Trailing 12M Revenue (USD) | $46M | $418,000 | Scale | |
| Gross Profit Margin (TTM) | 70.1% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.9x EV/Rev | 0.70x PEG · 115.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$9.1M ($8.9M Net Debt (3.44x D/E)) | -$20M ($1.5M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MBOT +5.71 pp
3M Horizon
MYO +12.4 pp
6M Horizon
MYO +38.21 pp
1Y Horizon
MYO +76.88 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MYO Revenue | MBOT Revenue | MYO Op. Margin | MBOT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -430.8% | N/A | MYO |
| FY2019 | $0M | N/A | -281.3% | N/A | MYO |
| FY2020 | $10M | N/A | -138.5% | N/A | MYO |
| FY2021 | $10M | N/A | -74.1% | N/A | MYO |
| FY2022 | $20M | N/A | -68.6% | N/A | MYO |
| FY2023 | $20M | N/A | -42.8% | N/A | MYO |
| FY2024 | $30M | N/A | -19.1% | N/A | MYO |
| FY2025 | $40M | N/A | -35.2% | N/A | MYO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MYO
UNCLASSIFIED
Current IV
266.0%
IV Percentile
81st %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MBOT
BREAKDOWN
Current IV
112.5%
IV Percentile
30th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact MBOT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MYO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MBOT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MYO vs MBOT Key Questions & Quantitative Answers
As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over Microbot Medical, Inc. (MBOT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas MBOT carries 54.9/100 (HOLD) at $0.68 (31.8x Forward P/E, -5057.2% operating margin). Composite vs. Pillar Nuance: While MBOT currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -5057.2% operating margin) and revenue trajectory (+22.2% vs. +0.0% YoY). Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile MBOT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MYO leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with MBOT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $418,000 TTM revenue (N/A gross margin, -5057.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while MBOT shifted N/A. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MBOT.
MBOT screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas MBOT trades at 31.8x Forward P/E, 31.8x Trailing P/E, 0.70x PEG, and 115.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus MBOT (-26.3% ROE) capital efficiency.
In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, MBOT carries 112.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 145% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MBOT vs MYO · Reverse Pair
MBOT vs MBRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal